DOTA-biotin pharmacokinetic parameters
. | 111In pharmacokinetics . | . | . | . | 90Yttrium pharmacokinetics . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients . | Vd, mL . | Clearance, mL/h . | T1/2 alpha, h . | T1/2 beta, h . | Vd, mL . | Clearance, mL/h . | T1/2 alpha, h . | T1/2 beta, h . | ||||||
Cohort A | ||||||||||||||
2 | 5 361 | 1 538 | 0.45 | 18 | 5 690 | 1 883 | 0.48 | 19 | ||||||
3 | 4 682 | 1 146 | 0.41 | 20 | 5 545 | 1 675 | 0.52 | 20 | ||||||
Average | 5 021 | 1 342 | 0.43 | 20 | 5 617 | 1 779 | 0.50 | 19 | ||||||
SD | ||||||||||||||
Cohort B | ||||||||||||||
4 | 3 616 | 2 435 | 0.22 | 13 | 4 019 | 3 341 | 0.22 | 10 | ||||||
5 | 15 300 | 1 611 | 1.56 | 30 | 14 829 | 1 871 | 1.47 | 23 | ||||||
6 | 13 829 | 4 583 | 0.15 | 13 | 11 631 | 3 926 | 0.17 | 14 | ||||||
8 | 9 293 | 1 265 | 0.90 | 43 | 9 303 | 2 083 | 0.88 | 24 | ||||||
Average | 10 509 | 2 473 | 0.71 | 25 | 9 946 | 2 805 | 0.69 | 18 | ||||||
SD | 5 259 | 1 490 | 0.66 | 15 | 4 554 | 989 | 0.62 | 7 | ||||||
Cohort C | ||||||||||||||
9 | 18 524 | 6 150 | 0.80 | 15 | 21 773 | 6 400 | 0.72 | 18 | ||||||
10 | 15 603 | 1 664 | 0.69 | 46 | 14 275 | 1 306 | 0.73 | 47 | ||||||
11 | 10 823 | 2 435 | 0.58 | 18 | 12 932 | 3 318 | 0.68 | 18 | ||||||
12 | 10 506 | 1 501 | 0.55 | 35 | 10 704 | 1 780 | 0.56 | 33 | ||||||
Average | 13 869 | 2 937 | 0.65 | 29 | 14 921 | 3 201 | 0.67 | 29 | ||||||
SD | 3 892 | 2 180 | 0.12 | 15 | 4 799 | 2 299 | 0.08 | 14 | ||||||
Cohort D | ||||||||||||||
13 | 10 080 | 2 002 | 0.51 | 30 | 9 068 | 1 871 | 0.54 | 31 | ||||||
14 | 9 497 | 2 089 | 0.56 | 23 | 9 081 | 1 965 | 0.55 | 28 | ||||||
15 | 15 802 | 4 192 | 0.67 | 13 | 12 309 | 2 834 | 0.73 | 14 | ||||||
Average | 11 793 | 2 761 | 0.58 | 22 | 10 153 | 2 223 | 0.60 | 24 | ||||||
SD | 3 484 | 1 240 | 0.08 | 9 | 1 867 | 531 | 0.10 | 9 | ||||||
Overall average | 10 995 | 2 508 | 0.62 | 24 | 10 858 | 2 635 | 0.63 | 23 | ||||||
Overall SD | 4 656 | 1 520 | 0.35 | 11 | 4 691 | 1 377 | 0.32 | 10 |
. | 111In pharmacokinetics . | . | . | . | 90Yttrium pharmacokinetics . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients . | Vd, mL . | Clearance, mL/h . | T1/2 alpha, h . | T1/2 beta, h . | Vd, mL . | Clearance, mL/h . | T1/2 alpha, h . | T1/2 beta, h . | ||||||
Cohort A | ||||||||||||||
2 | 5 361 | 1 538 | 0.45 | 18 | 5 690 | 1 883 | 0.48 | 19 | ||||||
3 | 4 682 | 1 146 | 0.41 | 20 | 5 545 | 1 675 | 0.52 | 20 | ||||||
Average | 5 021 | 1 342 | 0.43 | 20 | 5 617 | 1 779 | 0.50 | 19 | ||||||
SD | ||||||||||||||
Cohort B | ||||||||||||||
4 | 3 616 | 2 435 | 0.22 | 13 | 4 019 | 3 341 | 0.22 | 10 | ||||||
5 | 15 300 | 1 611 | 1.56 | 30 | 14 829 | 1 871 | 1.47 | 23 | ||||||
6 | 13 829 | 4 583 | 0.15 | 13 | 11 631 | 3 926 | 0.17 | 14 | ||||||
8 | 9 293 | 1 265 | 0.90 | 43 | 9 303 | 2 083 | 0.88 | 24 | ||||||
Average | 10 509 | 2 473 | 0.71 | 25 | 9 946 | 2 805 | 0.69 | 18 | ||||||
SD | 5 259 | 1 490 | 0.66 | 15 | 4 554 | 989 | 0.62 | 7 | ||||||
Cohort C | ||||||||||||||
9 | 18 524 | 6 150 | 0.80 | 15 | 21 773 | 6 400 | 0.72 | 18 | ||||||
10 | 15 603 | 1 664 | 0.69 | 46 | 14 275 | 1 306 | 0.73 | 47 | ||||||
11 | 10 823 | 2 435 | 0.58 | 18 | 12 932 | 3 318 | 0.68 | 18 | ||||||
12 | 10 506 | 1 501 | 0.55 | 35 | 10 704 | 1 780 | 0.56 | 33 | ||||||
Average | 13 869 | 2 937 | 0.65 | 29 | 14 921 | 3 201 | 0.67 | 29 | ||||||
SD | 3 892 | 2 180 | 0.12 | 15 | 4 799 | 2 299 | 0.08 | 14 | ||||||
Cohort D | ||||||||||||||
13 | 10 080 | 2 002 | 0.51 | 30 | 9 068 | 1 871 | 0.54 | 31 | ||||||
14 | 9 497 | 2 089 | 0.56 | 23 | 9 081 | 1 965 | 0.55 | 28 | ||||||
15 | 15 802 | 4 192 | 0.67 | 13 | 12 309 | 2 834 | 0.73 | 14 | ||||||
Average | 11 793 | 2 761 | 0.58 | 22 | 10 153 | 2 223 | 0.60 | 24 | ||||||
SD | 3 484 | 1 240 | 0.08 | 9 | 1 867 | 531 | 0.10 | 9 | ||||||
Overall average | 10 995 | 2 508 | 0.62 | 24 | 10 858 | 2 635 | 0.63 | 23 | ||||||
Overall SD | 4 656 | 1 520 | 0.35 | 11 | 4 691 | 1 377 | 0.32 | 10 |
Vd indicates volume of distribution; T1/2, half-life.